< Retour aux actualités
EA Pharma pursue its international expansion with the acquisition of the Italian brand Stardea

EA Pharma pursue its international expansion with the acquisition of the Italian brand Stardea

1 July 2022

EA Pharma, a reference player in Oligotherapy, Health Supplements, Active & Organic Nutrition and Cosmetics, announces today that it has completed its second international build-up with the acquisition of the Italian brand Stardea from Cooper Consumer Health.

With a history of 70+ years and renowned for its expertise in Oligotherapy, EA Pharma is a European leading pharmaceutical lab specialized in natural and efficient health nutrition.

EA Pharma covers 3 main areas through a diversified portfolio of drugs and food supplements:

  • Oligotherapy: pioneer and undisputed leader in oligotherapy with both MA and food supplements through 2 recognized brands Granions and Labcatal ;
  • Health Supplements: leading position in several sub segments under its 2 umbrella brands, Granions (France) and Drasanvi (Spain) ;
  • Active & Organic Nutrition: comprehensive portfolio of expert sports nutrition products;
  • Cosmetics : wide range of care products combining the Group’s know-how

French pharmacies are the historical and prevailing distribution channel, notwithstanding the fact that the Company has recently diversified its distribution network with e-commerce and exports now spanning 4 different continents.

 Founded in 2005 in Italy, Stardea is a historical and renowned player in the fields of nutraceuticals, medical devices and dermo cosmetics. With a high-end and concentrated product range characterized with quality, effectiveness and safety, its product portfolio is promoted by many doctors in Italy and sold in pharmacies.

This second international acquisition follows the successive takeovers of Nutrivercell (2017), PunchPower (2018) and Labcatal (2020) in France, and Drasanvi in Spain (2021).

“EA Pharma and Stardea share the DNA of developing high quality healthcare products recommended by healthcare professionals to patients. Our encounter was inevitable. This merger will further enhance innovations and growth for both entities in a very buoyant environment.” said Thierry Verne, CEO of EA Pharma.

“Stardea has made a significant contribution to the group over the past few years, thanks to the quality of its products and the commitment of its employees. The EA Pharma Group is the natural buyer of the company and we are convinced that it will take Stardea to a new dimension.” declared Yvan Vindevogel – Chairman of the Supervisory Board of Cooper Consumer Health.

“We are very proud of this second international step, which represents a unique opportunity for EA Pharma to penetrate the strategic Italian market and extend its European footprint with an already well-established brand. With the acquisition of Stardea, EA Pharma confirms its truly European profile.” said Patrick Eisenchteter, Managing Partner at Motion Equity Partners.